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Abstract
Background: Contraception is an important consideration for women with multiple sclerosis 
(MS); however, little is known about the possible effects of hormonal contraception on disease 
progression or other adverse outcomes (e.g., thrombosis, low bone mineral density).
Objective: To evaluate the evidence on the safety of contraceptive use among women with MS.
Search strategy: We searched the PubMed database for peer-reviewed articles published in any 
language from database inception through July 2015.
Selection criteria: We included studies that examined health outcomes among women 
diagnosed with MS initiating or continuing a contraceptive method. We excluded case reports and 
case series but included all other study designs.
Results: From 111 articles, we identified four studies (from 5 articles) that met our inclusion 
criteria. Evidence from one randomized controlled trial, two retrospective cohort studies, and one 
cross-sectional study suggests that use of combined oral contraceptives (COCs) or oral 
contraceptives (OCs) (type not specified) among women with MS does not worsen the clinical 
course of disease, defined as disability level, disease severity or progression, relapse or number of 
new brain lesions on magnetic resonance imaging (body of evidence grading Level I, fair to Level 
II-3, poor). No studies were identified that examined the safety of other contraceptive methods or 
examined other outcomes of interest (venous thromboembolism, changes in bone mineral density) 
related to contraceptive use among women with MS.
Conclusions: Limited evidence suggests that COC or OC use after MS onset does not worsen 
the clinical course of disease.
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1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system in 
which the immune system attacks the myelin, disrupting communication between the brain 
and the rest of the body. Symptoms of MS vary widely over time and among individuals, 
depending on the amount of damage and which nerves are affected. Symptoms may include 
optic neuritis, sensory and gait disturbances, muscle weakness, tremor, spasticity, vertigo, 
bladder dysfunction and fatigue [1].
The course of MS has been categorized into several disease patterns based on disease 
activity and progression [2,3]. Clinically isolated syndrome (CIS) is the first clinical 
presentation of a disease compatible with MS that has yet to fulfill diagnostic criteria. 
Relapsing remitting MS (RRMS) is characterized by clearly defined relapses with no disease 
progression in between. Secondary progressive MS (SPMS) is characterized by an initial 
RRMS disease course followed by progression with or without acute relapses. The last 
disease pattern is primary progressive MS (PPMS), characterized by disease progression 
from onset with occasional plateaus or temporary minor improvements, with or without 
acute relapses. PPMS accounts for approximately 10–20% of cases at onset [4]. The 
nonrelapsing patterns are associated with greater neurological disability.
Although data are not available on the prevalence of MS among women of reproductive age 
in the United States, estimates suggest that 135 persons per 100,000 in the United States 
have MS [5], which translates to roughly 435,000 people [6]. As women are affected 2.4 
times as often as men [7], we estimate that roughly 307,000 women in the United States 
have MS. Contraception is an important consideration for women with MS because the peak 
age of onset for women is during the childbearing years [8], and the disease does not impair 
fertility [9]. Further, since use of disease-modifying therapies to treat MS is generally not 
recommended for women seeking to achieve pregnancy and some are known teratogens 
[10], use of effective contraception is important to prevent unintended pregnancies among 
women using these treatments.
Most epidemiological evidence suggests no association between oral contraceptive (OC) use 
and risk of developing MS [11]; however, these data do not provide information on possible 
effects of hormonal contraception in women with MS, including disease progression or other 
adverse outcomes. MS patients have increased risk for venous thromboembolism (VTE) due 
to disability, immobility and autoinflammatory processes [12,13], which may be further 
increased with combined hormonal contraceptive use. MS patients may also have 
compromised bone health [14], so use of progestin-only injectables may be of concern. On 
the other hand, endogenous and exogenous hormonal exposures have been shown to 
stabilize MS [15,16]; thus, hormonal contraceptive use may positively affect the MS disease 
course.
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The U.S. Centers for Disease Control and Prevention (CDC) publishes the U.S. Medical 
Eligibility Criteria for Contraceptive Use (US MEC) [17], which provides evidence-based 
guidance on the safety of contraceptive methods for women with certain characteristics or 
medical conditions. Currently, the US MEC does not include recommendations for 
contraceptive use by women with MS. As part of a process to update the US MEC, the 
objective of this systematic review was to evaluate the evidence on the safety of 
contraceptive use among women with MS.
2. Materials and methods
We conducted this systematic review according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18]. Our key question was 
whether women of reproductive age with MS using a specific contraceptive method are at 
increased risk for adverse outcomes (e.g., relapse, disease progression, VTE, change in bone 
mineral density) compared with women using a different method or no method of 
contraception.
2.1. Literature search
We searched the PubMed database for peer-reviewed articles published in any language 
from database inception through June 2015 on the safety of using any contraceptive method 
among women with MS, using the following search strategy:
(((((((((((contracept* OR mirena) OR ((((“Norpregnanes”[Mesh] OR (“Contraceptive 
Agents”[Mesh] OR “Contraceptive Agents “[Pharmacological Action])) OR “Contraceptive 
Devices”[Mesh]) OR “Contraception” [Mesh])))) OR ((((((progest*)) OR ((((“Progestins”
[Mesh] OR “Progesterone Congeners”[Mesh])) OR “Progesterone”[Mesh])))) AND 
(((contracept*) OR ((((“Norpregnanes”[Mesh] OR (“Contraceptive Agents”[Mesh] OR 
“Contraceptive Agents “[Pharmacological Action])) OR “Contraceptive Devices”[Mesh]) 
OR “Contraception” [Mesh]))))))) OR (((((((((dmpa)) OR ((depo-provera))) OR 
((norethisterone enanthate)))) OR ((“Medroxyprogesterone 17-Acetate”[Mesh])))) AND 
(((contracept*) OR ((((“Norpregnanes”[Mesh] OR (“Contraceptive Agents”[Mesh] OR 
“Contraceptive Agents “[Pharmacological Action])) OR “Contraceptive Devices”[Mesh]) 
OR “Contraception” [Mesh]))))))) OR ((((iud)) OR ((“Intrauterine Devices” [Mesh]))))) OR 
((((emergency contraception)) OR ((“Contraception, Postcoital”[Mesh] OR “Contraceptive 
Agents”[Mesh]))))) OR ((((nuvaring)) OR (((“Desogestrel”[Mesh] OR “Contraceptive 
Agents, Female”[Mesh]) OR “Contraceptive Devices, Female”[Mesh]))))) OR (((((hormonal 
patch)) OR ((ortho evra))) OR (((“Norges- trel”[Mesh] OR “Contraceptive Devices, Female”
[Mesh]) OR “Contraceptive Agents, Female”[Mesh]))))))) AND (((“Multiple Sclerosis”
[Mesh] OR “Multiple Sclerosis, Relapsing–Remitting”[Mesh] OR “Multiple Sclerosis, 
Chronic Progressive”[Mesh])) OR “multiple sclerosis”)
In addition, we hand-searched reference lists from articles identified by the search and key 
review articles.
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2.2. Selection criteria
We reviewed titles as well as abstracts to identify studies examining the safety of using any 
contraceptive method among women with MS. We included studies that examined health 
outcomes among women diagnosed with MS initiating or continuing a contraceptive 
method. We excluded case reports and case series but included all other study designs.
2.3. Study quality assessment and data synthesis
The evidence was summarized and systematically assessed using standard abstraction forms. 
The quality of each individual piece of evidence was assessed using the grading system 
developed by the United States Preventive Services Task Force [19]. We focused on several 
study factors when assessing quality, including study design, diagnostic criteria for MS, 
assessment of contraceptive use, outcome assessment, adjustment for potential confounders, 
timing of contraceptive use relative to outcome assessment and participation and follow-up 
(FU) rates. We did not compute summary measures of association due to heterogeneity 
across the included studies related to study population, study design, classification of 
exposure and outcomes reported.
3. Results
The search strategy identified 111 articles, of which four studies [20–23] (from five articles 
[20–24]) met our inclusion criteria. Two articles are described together as a single piece of 
evidence since both reported findings from the same project and included overlapping 
samples of women [21,24]. Excluded studies were mainly review papers and papers not 
relevant to our key question. Three studies were excluded because it was unclear if 
contraceptive use occurred after MS diagnosis [25–27].
Each of the four included studies examined OCs, two of which specified the type as 
combined oral contraceptives (COCs) [20,22]. One study examined the effect of COCs as an 
add-on therapy in patients taking interferon β−1a [22]. We did not identify studies that 
examined the safety of other contraceptive methods among women MS.
Of the four included studies, one was a randomized controlled trial (RCT) rated as having 
fair quality [22], two were retrospective cohort studies rated as having fair quality [20,23] 
and one was a cross-sectional study rated as having poor quality [21]. All studies examined 
some aspect of the clinical course of MS (e.g., disability, severity/disease progression, 
annualized relapse rate, brain lesions). Sample sizes in the four studies ranged from 132 [23] 
to 512 [21]. Study participants had different types of MS including RRMS [22,23] and 
RRMS at onset, some of which had progressed to SPMS [20]. One study did not specify the 
type of MS [21]. No studies were included among women with PPMS or CIS. Table 1 
describes the details of each study.
The RCT examined the effect of COCs as an add-on therapy in 149 women with RRMS 
taking interferon β−1a subcutaneously [22]. Women were randomized into one of three 
study groups: (a) no COC; (b) low-dose COC [20-mcg ethinyl estradiol (EE)]; or (c) higher 
dose COC (40-mcg EE). The sample was recruited from five MS medical centers, and 
women had a mean age of ~30 years with a mean disease duration of ~3–4 years; baseline 
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disability was fairly low. The primary outcome of interest was the cumulative number of 
combined unique active lesions (CUALs), an accepted marker of inflammation, on brain 
magnetic resonance imaging (MRI) at 96 weeks. Secondary outcomes included the number 
of CUALs at 48 weeks, the annualized relapse rate from week 0–96, the proportion of 
women with sustained disability progression and adverse events. Overall, 99% of women 
completed 96 weeks of FU. The treatment completion rate for interferon β−1a was 90%, 
88% and 92% for Groups 1, 2 and 3, respectively. The treatment completion rate for COC 
use was 76% for Group 2 and 73% for Group 3. The time at which treatment was 
discontinued was also comparable between study groups. The mean (median) duration of 
interferon β−1a treatment was 23.1 (24), 21.9 (24) and 23.8 (24) months in Groups 1, 2 and 
3, respectively; and the mean (median) duration of COC use was 20.6 (24) months in Group 
2 and 19.3 (24) months in Group 3. Reasons for interferon β−1a discontinuation included 
adverse events, disease progression, loss to FU and pregnancy; similar information on 
reasons for COC discontinuation were not reported for all discontinuers. The primary 
outcome only was analyzed using the intention-to-treat subgroup, which included all 
patients treated with at least one dose of interferon β−1a. Results showed the cumulative 
number of CUALs (defined as new nonenhancing T2-weighted lesions or new gadolinium- 
enhancing T1-weighted lesions) at week 96 varied by study group (0.98, 0.85 and 0.72 for 
Groups 1, 2 and 3, respectively), representing a relative reduction of 14.1% comparing 
Group 2 (20-mcg COC) versus 1 (no COC) (p= .24) and 26.5% comparing Group 3 (40-mcg 
dose COC) versus 1 (no COC) (p=.04); these findings were adjusted for age, number of 
gadolinium-enhancing lesions and baseline disability. No significant differences were 
observed at week 48. Further, no significant differences in the annualized relapse rate from 
week 0–96 or in sustained disability progression were observed between study groups after 
adjustment for confounders. Of note, although the incidence of interferon β−1a-related 
adverse events was similar between study groups as was the incidence of COC-related 
adverse events among the 20-mcg and 40-mcg COC groups (no details provided), one 
woman in the 20-mcg COC group prematurely discontinued COC use due to an episode of 
deep venous thrombosis (DVT); no other details about the woman or DVT episode were 
provided.
The first retrospective cohort study examined the effect of at least 1 year of continuous OC 
use (type not specified) before or after disease onset (DO) on disability, severity and 
annualized relapse rates among 132 women with RRMS before receiving disease-modifying 
treatment (DMT) [23]. Disability at the time of the study was measured by the Expanded 
Disability Status Scale (EDSS) [28], which ranges from 0 (normal neurologic exam) to 10 
(death due to MS), and severity at the time of the study was measured by the MS Severity 
Score (MSSS) [29], which is based on the EDSS score but adjusted for disease duration. The 
sample included women from an outpatient clinic at a university hospital first examined in 
1995–2010. All women had at least 2 years of disease duration (mean of 6.2 years), and 
none had been treated with steroids for at least 1 month. Women were categorized as never 
OC users (n=52), OC users only before DO (n=26) or OC users after DO (n=54), 83% of 
whom began OC use before DO. After adjustment for confounders (i.e., age at DO, disease 
duration, smoking status, age at menarche), OC users after DO had significantly (p<.05) 
lower EDSS and MSSS values versus never OC users. MSSS values were dichotomized, and 
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women with values <2.5 were considered to have a more benign disease course. After 
adjustment for confounders, OC users after DO had significantly (p<.05) increased odds of 
having a benign disease course versus never OC users and OC users only before DO 
combined [adjusted odds ratio (AOR)=2.97, 95% confidence interval (CI)=1.24, 6.54]. No 
association was found between OC group and annualized relapse rates.
The second retrospective cohort study also examined the effect of at least 1 year of 
continuous OC use before or after DO on disability, severity and annualized relapse rates 
among women with RRMS at onset [20]. The study specifically examined the effect of 
COCs and additionally included progression to SPMS as an outcome. Disability at the time 
of the study was measured by the EDSS [28], and severity at the time of the study was 
measured by the MSSS [29]. The sample included 174 women from an academic medical 
center with at least 1 year of disease duration (mean of 14.3 years); 59% had ever used 
DMT. Women were categorized as never COC users (n=63), COC users only before DO 
(n=33), COC users before and after DO (n=44) or COC users only after DO (n=34). Among 
COC users, the median duration of use was 7 years ranging from 1 to 32 years. COC users 
before and after DO had significantly (p<.05) less disability versus never users 
(EDSS=2.3±1.6 vs. 3.4±2.2, respectively). COC users only after DO also had lower 
disability scores (EDSS=2.5±1.6) versus never users, but findings were not statistically 
significant. Survival analysis adjusted for a wide range of confounders (i.e., age, disease 
duration, DMT use, age at menarche, parity) found a significantly lower probability of 
progression to SPMS in COC users before and after DO versus never COC users (p=.015) 
and in COC users only after DO versus never COC users (p=.008). Disease severity and 
annualized relapse rates did not significantly differ between groups. Last, among COC users 
before and after DO and only after DO combined (n=78), total duration of COC use after 
onset was significantly (p=.0005) associated with lower disability but not severity.
The cross-sectional study examined the effect of at least 3 months of OC use (type not 
specified) after DO on MS disease course [21]. The type of MS was not specified. Outcomes 
included self-reported worsening of symptoms and severity/disease progression calculated 
by dividing the level of disability measured by the Kurtzke scale (the predecessor of the 
EDSS) [30] by years of disease duration. The sample included 512 women from an 
outpatient clinic. Among OC users after DO (n=151), 14% reported worsening of 
symptoms; the proportion of non-OC users after DO reporting worsening of symptoms was 
not reported. For reasons not described, only a subset of women were included in the disease 
progression analysis (n=312), including only 60% of OC users after DO. In this analysis, 
disease progression did not differ significantly (p>.05) between four groups defined by OC 
use and/or pregnancy after DO (only OC use after DO, only pregnancy after DO, OC use 
and pregnancy after DO and neither OC use or pregnancy after DO).
4. Discussion
We identified four studies rated as having fair to poor quality that examined OC use among 
women with MS, all of which suggest that OCs do not negatively affect disease course [20–
23]. Two retrospective cohort studies found no detrimental influence of at least 1 year of 
continuous OC use after DO on disability levels [20,23], both of which found less disability 
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among OC users compared with never users. Total duration of COC use after DO was also 
found to be significantly associated with lower disability in one study [20]. All four included 
studies examined the effect of OCs on some aspect of disease severity or progression with 
none finding a negative effect and two retrospective cohort studies suggesting a positive 
effect [20,23]. Three studies, including one RCT, examined the influence of OCs on relapse 
rates, none finding significant associations [20,22,23]. One RCT examined the effect of 
COC use among women taking interferon β−1a and found that the cumulative number of 
unique active brain lesions detected by MRI at 24 months was significantly lower among 
women taking 40-mcg COCs versus no COCs [22]. COCs were not harmful except that one 
woman taking low-dose COCs prematurely discontinued use due to a DVT that may or may 
not have been related to COC use. No studies were identified that examined the safety of 
other contraceptive methods or examined other outcomes of interest, including VTE or 
changes in bone mineral density, related to contraceptive use among women with MS.
This body of evidence has several limitations. OC use was self-reported by women and 
subject to recall error in two studies [20,21], and the type of OCs examined were not 
reported in two studies [21,23]. As some evidence from this review suggests that the total 
duration of OC use significantly reduces disability [20], it is limiting that two studies did not 
report on the total duration of OC use beyond the specified time period (e.g., 3 months, 1 
year) [21,23]. In addition, the timing of OC use relative to outcome measurement was not 
reported in three studies, thus women may not have been using OCs at the time outcomes 
were assessed [20,21,23]. Further, the two retrospective cohort studies that reported 
beneficial effects of OCs may have observed lower disease disability and severity/
progression among OC users because of a “healthy user” bias in which women with less 
severe disease chose to use OCs or needed contraception because they were healthy enough 
to engage in sexual activity. Additional studies would be needed to confirm the beneficial 
effects of OCs found in these studies. Other limitations of the studies in this body of 
evidence include samples of women from a single center [20,21,23], not describing the MS 
diagnostic criteria used [21,22] and not indicating if women were using therapeutic 
medications that may have impacted outcomes under investigation [21]. Last, the RCT that 
found beneficial effects of 40-mcg COCs among women on interferon β−1a may not be 
generalizable to women not taking this treatment, since it is unknown whether 40-mcg 
COCs enhance the effect of interferon β−1a or if interferon β−1a predisposes the immune 
system to potential positive effects of COCs.
Additional studies not meeting our inclusion criteria were identified that may provide 
relevant indirect evidence. Three case reports [31–33] were identified that describe episodes 
of cerebral venous thrombosis among women with MS. In one case report, two women aged 
23 and 19 years taking OCs (type not reported) with last high dose corticosteroid use within 
48 h and a lumbar puncture within 4–6 days experienced cerebral venous thrombosis [31]. 
OC use was considered a vascular risk factor, but the authors proposed that the lumbar 
puncture and high dose corticosteroids were the major contributory factors. In the second 
case report, one woman aged 46 years with no cerebrovascular risk factors other than COC 
use (35-mcg EE) was hospitalized where she was diagnosed as having MS and underwent 
lumbar puncture and received high doses of corticosteroids intravenously; the woman 
developed cerebral venous thrombosis and passed away [32]. The authors attributed the 
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outcome largely to the lumbar puncture which can slow venous flow and tear the venous 
sinuses predisposing one to develop a cerebral venous thrombosis, but also mentioned the 
possible role of high dose corticosteroids. In the third case report, a woman aged 35 years 
with a history of using OCs (type not reported) for approximately 8 years, no history of 
cigarette smoking and recent prednisone use experienced intracranial transverse and sigmoid 
sinus thromboses and, later, DVT of the calf [33]. In their concluding remarks, the authors 
discouraged COC use among MS patients with decreased mobility due to increased risk for 
DVT.
Six additional studies provide potentially relevant indirect evidence, five of which examined 
or described changes in MS symptoms related to cyclical hormonal changes [34–38] and one 
of which examined the effect of the pregnancy hormone estriol among women with MS [16]. 
Two prospective cohort studies, from the same institution but among different samples of 
COC users, examined MS symptoms over three cycles [34,38]. In the first cohort study 
(n=7), women reported significantly higher symptom scores for weakness, numbness and 
tiredness (out of 13 total symptoms) during the hormone-free interval compared with weeks 
COCs were taken daily [34]. In the second cohort study (n=22), women reported 
significantly higher symptom scores for weakness, vertigo, urinary symptoms and stiffness 
(out of 10 total symptoms) during the hormone-free interval compared with weeks COCs 
were taken daily [38]. Findings from both suggest a positive effect of the COC steroids on 
MS symptoms. Two cross-sectional studies by the same authors examined OC use among 
women with and without premenstrual exacerbation of MS symptoms [35,36]. Whereas the 
earlier report found significantly higher OC use among women reporting no influence of the 
premenstrual period on MS symptoms suggesting a protective effect [35], the later report 
found no difference in OC use between groups [36]. The fourth study, a case report, 
described the suppression of monthly exacerbations of MS symptoms through the use of 
norethynodrel (Enovid-E) for more than 2 years among a woman aged 36 years who only 
experienced exacerbations during onset of menstruation [37]. The last study providing 
indirect evidence was a cross-over trial examining the effect of estriol in 10 women with 
RRMS [16]. Compared with baseline, women treated with 8 mg/day of oral estriol for 6 
months experienced significant decreases in gadolinium-enhancing lesions, a favorable 
immune response and improved cognition.
Evidence on the effect of pregnancy on MS disease course may also be relevant. MS 
typically stabilizes during pregnancy, with lower relapse rates versus prepregnancy, 
particularly during the third trimester when circulating levels of estrogens and progestins are 
highest; but aggravation of symptoms is often seen during the first 3 months postpartum 
when hormone levels drop [15]. The beneficial effect of pregnancy on MS disease course 
may also be related to changes in the immune system during pregnancy.
The exact mechanism through which hormones may exert a protective effect on MS disease 
course is not fully understood. In laboratory animals with experimental autoimmune 
encephalomyelitis, a spectrum of neurological disorders used to model MS [39], estrogens 
and progestins have shown antiinflammatory and neuroprotective effects [40,41]. It has also 
been suggested that estrogens could affect nerve conduction [15]. More research is needed to 
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better understand the effect of endogenous and exogenous hormonal exposures, including 
hormonal contraceptives, on MS prognosis.
No evidence was found examining the effect of combined hormonal contraceptives on VTE 
risk among women with MS. Data from population-based, matched cohort studies from the 
United Kingdom and Sweden suggest that compared with those without MS, MS patients 
have an approximately threefold increased risk of VTE [12] or DVT [13], with lower risk 
found among females than males in one study [VTE adjusted hazard ratio (AHR) = 2.28, 
95% CI = 1.73, 3.00 for females vs. AHR=3.16, CI=2.18, 4.57 for males] [12]. VTE risk 
also varies by MS type, with increased risk of DVT among those with progressive forms of 
the disease [relative risk (RR) = 3.57, CI=1.95, 6.56 for PPMS, RR=3.41, CI=2.45, 4.75 for 
SPMS, and RR=2.16, CI=1.21, 3.87 for RRMS] [13]. Among MS patients (females and 
males combined), risk factors for VTE included history of varicose veins, a prior VTE, 
obesity and recent (past 6 months) major trauma, spasticity, disability and corticosteroid use 
[12]. In this study, immobility was not examined separately but was considered as part of 
disability and spasticity which both interfere with normal movement. Immobility is a known 
major risk factor for thrombosis [42] and likely plays an important role leading to the 
increased risk of VTE among MS patients, especially given the elevated risks of DVT 
among MS patients with progressive forms of the disease [13].
Another theoretical concern for which no evidence was found was the impact of progestin-
only injectables, which may be associated with small but reversible changes in bone mineral 
density in the general population [43], on bone mineral density and fracture risk among 
women with MS. Bone health among MS patients may be compromised due to disease-
related disability, immobility, use of corticosteroids and fracture risk high due to poor bone 
health and increased probability of falls secondary to weakness and ataxia [44]. Data from a 
population-based, matched-cohort study from the United Kingdom suggest that compared 
with controls, MS patients have a 1.2-fold increased risk of any fracture after adjustment, 
with higher risk for hip fracture (AHR=2.79, CI=1.83, 4.26) and osteoporotic fracture 
(AHR=1.35, CI=1.13, 1.62), defined as a fracture of the radius/ulna, vertebrae, femur, hip, 
humerus, pelvis or ribs [45]. Among females aged 18–49 years with MS specifically, the 
median 5-year risk of osteoporotic fracture was 1.6% [45].
In conclusion, evidence from one RCT rated as having fair quality, two retrospective cohort 
studies rated as having fair quality and one cross-sectional study rated as having poor quality 
suggests that use of COCs or OCs (type not specified) among women with MS does not 
worsen the clinical course of disease (body of evidence grading Level I, fair to Level II-3, 
poor). No evidence was identified that examined the safety of other contraceptive methods 
or examined other outcomes of interest (VTE, changes in bone mineral density) related to 
contraceptive use among women with MS. The evidence base would be strengthened by the 
development of additional studies with strong designs that examine a broader range of 
contraceptive methods and outcomes, report the timing of contraceptive use relative to 
outcome measurement and include women with different types of MS. The information in 
this review was presented to an expert panel in August 2015 at a meeting held by the CDC 
and will be incorporated into the forthcoming update of the US MEC.
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